Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Affiliations

• ¹ ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ztian1@mdanderson.org.
• ² ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
• ⁵ ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.
• ⁶ Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.
• ⁷ ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jmolldre@mdanderson.org.
• ⁸ Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jmolldre@mdanderson.org.